drug
ketotifen fumarate
Marketedupdated 3mo agoby Sentiss Pharmaceuticals LLC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying ketotifen fumarate
- phase3A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis
- phase3Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution
- phase3Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis
- phase3Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 27, 2028
~1.7 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Jun 27, 2030formulationUS 99623763.9y
- Mar 27, 2028formulationUS 94747461.7y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2m ago
Found something off?
comments(0)
5-min edit window · permanent after that